Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation

Keren Borensztajn*, Maikel P. Peppelenbosch, C. Arnold Spek

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Scopus)


Previously, we showed that activated coagulation factor X (FXa) inhibits migration of breast, lung and colon cancer cells. We showed that the effect of FXa on migration was protease-activated receptor (PAR)-1-dependent, but the subsequent cellular signaling routes remained elusive. In the current manuscript, we show that both the Rho/ROCK and Src/FAK/paxillin pathways are required for FXa-mediated inhibition of breast cancer cell migration. FXa induced pronounced stress fiber formation that was partially inhibited by pre-treatment with specific ROCK or Src inhibitors. Downstream of Rho/ROCK and Src/FAK/paxillin, FXa induced myosin light chain phosphorylation and LIMK1 activation resulting in cofilin inactivation. Knocking-down LIMK1 expression abolished FXa-induced inhibition of cell invasion. Our results reveal that FXa-mediated sustained cofilin inactivation leads to stabilization of actin filaments incompatible with migration. Overall we confirm that, beyond its role in blood coagulation, FXa plays a key role in cell migration and we unravel a new mechanism of PAR-1-mediated inhibition of migration via Rho and Src dependent pathways.

Original languageEnglish
Pages (from-to)e323-e328
JournalThrombosis Research
Issue number6
Publication statusPublished - Jun 2010
Externally publishedYes


Dive into the research topics of 'Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation'. Together they form a unique fingerprint.

Cite this